カテゴリー： GlobalInfoResearch, 世界, 医療/バイオ

世界の遺伝性疾患薬市場2022年：嚢胞性線維症（CF）、デュシェンヌ型筋ジストロフィー（DMD）、リソソーム蓄積症（LSD）、発作性夜間ヘモグロビン尿症（PNH）

◆英語タイトル：Global Genetic Disorders Drug Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

GlobalInfoResearchが発行した調査報告書（GIR22MY8831）◆商品コード：GIR22MY8831
◆発行会社（リサーチ会社）：GlobalInfoResearch
◆発行日：2022年5月（※2025年版があります。お問い合わせください。）
◆ページ数：91
◆レポート形式：英語 / PDF
◆納品方法：Eメール（注文後2-3日）
◆調査対象地域：グローバル
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

遺伝性疾患薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の遺伝性疾患薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

遺伝性疾患薬市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・嚢胞性線維症（CF）、デュシェンヌ型筋ジストロフィー（DMD）、リソソーム蓄積症（LSD）、発作性夜間ヘモグロビン尿症（PNH）

用途別セグメントは次のように区分されます。
・クリニック、病院

世界の遺伝性疾患薬市場の主要な市場プレーヤーは以下のとおりです。
・Sanofi、Vertex、Takeda、Amgen、GW Pharmaceuticals、Pfizer、BioMarin、Sarepta

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、遺伝性疾患薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な遺伝性疾患薬メーカーの企業概要、2019年～2022年までの遺伝性疾患薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な遺伝性疾患薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別遺伝性疾患薬の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの遺伝性疾患薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での遺伝性疾患薬市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および遺伝性疾患薬の産業チェーンを掲載しています。
・第13、14、15章では、遺伝性疾患薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
・メーカー情報（企業概要、製品概要、販売量、価格、売上）：Sanofi、Vertex、Takeda、Amgen、GW Pharmaceuticals、Pfizer、BioMarin、Sarepta
・メーカー別市場シェア
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：嚢胞性線維症（CF）、デュシェンヌ型筋ジストロフィー（DMD）、リソソーム蓄積症（LSD）、発作性夜間ヘモグロビン尿症（PNH）
・用途別分析2017年-2028年：クリニック、病院
・遺伝性疾患薬の北米市場規模2017年-2028年：アメリカ、カナダ、メキシコ
・遺伝性疾患薬のヨーロッパ市場規模2017年-2028年：ドイツ、イギリス、フランス、ロシア、イタリア
・遺伝性疾患薬のアジア市場規模2017年-2028年：中国、日本、韓国、インド、東南アジア、オーストラリア
・遺伝性疾患薬の南米市場規模2017年-2028年：ブラジル、アルゼンチン
・遺伝性疾患薬の中東・アフリカ市場規模2017年-2028年：サウジアラビア、トルコ、エジプト、南アフリカ
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Genetic Disorders Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Genetic Disorders Drug market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Clinic accounting for % of the Genetic Disorders Drug global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Cystic Fibrosis (CF) segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Genetic Disorders Drug include Sanofi, Vertex, Takeda, Amgen, and GW Pharmaceuticals, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Genetic Disorders Drug market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Cystic Fibrosis (CF)
Duchenne Muscular Dystrophy (DMD)
Lysosomal Storage Disease (LSD)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Market segment by Application can be divided into
Clinic
Hospital
The key market players for global Genetic Disorders Drug market are listed below:
Sanofi
Vertex
Takeda
Amgen
GW Pharmaceuticals
Pfizer
BioMarin
Sarepta
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Genetic Disorders Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Genetic Disorders Drug, with price, sales, revenue and global market share of Genetic Disorders Drug from 2019 to 2022.
Chapter 3, the Genetic Disorders Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Genetic Disorders Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Genetic Disorders Drug market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Genetic Disorders Drug.
Chapter 13, 14, and 15, to describe Genetic Disorders Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.

❖ レポートの目次 ❖

1 Market Overview
1.1 Genetic Disorders Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Genetic Disorders Drug Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Cystic Fibrosis (CF)
1.2.3 Duchenne Muscular Dystrophy (DMD)
1.2.4 Lysosomal Storage Disease (LSD)
1.2.5 Paroxysmal Nocturnal Hemoglobinuria (PNH)
1.3 Market Analysis by Application
1.3.1 Overview: Global Genetic Disorders Drug Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Clinic
1.3.3 Hospital
1.4 Global Genetic Disorders Drug Market Size & Forecast
1.4.1 Global Genetic Disorders Drug Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Genetic Disorders Drug Sales in Volume (2017-2028)
1.4.3 Global Genetic Disorders Drug Price (2017-2028)
1.5 Global Genetic Disorders Drug Production Capacity Analysis
1.5.1 Global Genetic Disorders Drug Total Production Capacity (2017-2028)
1.5.2 Global Genetic Disorders Drug Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Genetic Disorders Drug Market Drivers
1.6.2 Genetic Disorders Drug Market Restraints
1.6.3 Genetic Disorders Drug Trends Analysis
2 Manufacturers Profiles
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business
2.1.3 Sanofi Genetic Disorders Drug Product and Services
2.1.4 Sanofi Genetic Disorders Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Vertex
2.2.1 Vertex Details
2.2.2 Vertex Major Business
2.2.3 Vertex Genetic Disorders Drug Product and Services
2.2.4 Vertex Genetic Disorders Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Takeda
2.3.1 Takeda Details
2.3.2 Takeda Major Business
2.3.3 Takeda Genetic Disorders Drug Product and Services
2.3.4 Takeda Genetic Disorders Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Amgen
2.4.1 Amgen Details
2.4.2 Amgen Major Business
2.4.3 Amgen Genetic Disorders Drug Product and Services
2.4.4 Amgen Genetic Disorders Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 GW Pharmaceuticals
2.5.1 GW Pharmaceuticals Details
2.5.2 GW Pharmaceuticals Major Business
2.5.3 GW Pharmaceuticals Genetic Disorders Drug Product and Services
2.5.4 GW Pharmaceuticals Genetic Disorders Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business
2.6.3 Pfizer Genetic Disorders Drug Product and Services
2.6.4 Pfizer Genetic Disorders Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 BioMarin
2.7.1 BioMarin Details
2.7.2 BioMarin Major Business
2.7.3 BioMarin Genetic Disorders Drug Product and Services
2.7.4 BioMarin Genetic Disorders Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Sarepta
2.8.1 Sarepta Details
2.8.2 Sarepta Major Business
2.8.3 Sarepta Genetic Disorders Drug Product and Services
2.8.4 Sarepta Genetic Disorders Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Genetic Disorders Drug Breakdown Data by Manufacturer
3.1 Global Genetic Disorders Drug Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Genetic Disorders Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Genetic Disorders Drug
3.4 Market Concentration Rate
3.4.1 Top 3 Genetic Disorders Drug Manufacturer Market Share in 2021
3.4.2 Top 6 Genetic Disorders Drug Manufacturer Market Share in 2021
3.5 Global Genetic Disorders Drug Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Genetic Disorders Drug Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Genetic Disorders Drug Market Size by Region
4.1.1 Global Genetic Disorders Drug Sales in Volume by Region (2017-2028)
4.1.2 Global Genetic Disorders Drug Revenue by Region (2017-2028)
4.2 North America Genetic Disorders Drug Revenue (2017-2028)
4.3 Europe Genetic Disorders Drug Revenue (2017-2028)
4.4 Asia-Pacific Genetic Disorders Drug Revenue (2017-2028)
4.5 South America Genetic Disorders Drug Revenue (2017-2028)
4.6 Middle East and Africa Genetic Disorders Drug Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Genetic Disorders Drug Sales in Volume by Type (2017-2028)
5.2 Global Genetic Disorders Drug Revenue by Type (2017-2028)
5.3 Global Genetic Disorders Drug Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Genetic Disorders Drug Sales in Volume by Application (2017-2028)
6.2 Global Genetic Disorders Drug Revenue by Application (2017-2028)
6.3 Global Genetic Disorders Drug Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Genetic Disorders Drug Sales by Type (2017-2028)
7.2 North America Genetic Disorders Drug Sales by Application (2017-2028)
7.3 North America Genetic Disorders Drug Market Size by Country
7.3.1 North America Genetic Disorders Drug Sales in Volume by Country (2017-2028)
7.3.2 North America Genetic Disorders Drug Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Genetic Disorders Drug Sales by Type (2017-2028)
8.2 Europe Genetic Disorders Drug Sales by Application (2017-2028)
8.3 Europe Genetic Disorders Drug Market Size by Country
8.3.1 Europe Genetic Disorders Drug Sales in Volume by Country (2017-2028)
8.3.2 Europe Genetic Disorders Drug Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Genetic Disorders Drug Sales by Type (2017-2028)
9.2 Asia-Pacific Genetic Disorders Drug Sales by Application (2017-2028)
9.3 Asia-Pacific Genetic Disorders Drug Market Size by Region
9.3.1 Asia-Pacific Genetic Disorders Drug Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Genetic Disorders Drug Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Genetic Disorders Drug Sales by Type (2017-2028)
10.2 South America Genetic Disorders Drug Sales by Application (2017-2028)
10.3 South America Genetic Disorders Drug Market Size by Country
10.3.1 South America Genetic Disorders Drug Sales in Volume by Country (2017-2028)
10.3.2 South America Genetic Disorders Drug Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Genetic Disorders Drug Sales by Type (2017-2028)
11.2 Middle East & Africa Genetic Disorders Drug Sales by Application (2017-2028)
11.3 Middle East & Africa Genetic Disorders Drug Market Size by Country
11.3.1 Middle East & Africa Genetic Disorders Drug Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Genetic Disorders Drug Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Genetic Disorders Drug and Key Manufacturers
12.2 Manufacturing Costs Percentage of Genetic Disorders Drug
12.3 Genetic Disorders Drug Production Process
12.4 Genetic Disorders Drug Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Genetic Disorders Drug Typical Distributors
13.3 Genetic Disorders Drug Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Genetic Disorders Drug Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Genetic Disorders Drug Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Sanofi Basic Information, Manufacturing Base and Competitors
Table 4. Sanofi Major Business
Table 5. Sanofi Genetic Disorders Drug Product and Services
Table 6. Sanofi Genetic Disorders Drug Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Vertex Basic Information, Manufacturing Base and Competitors
Table 8. Vertex Major Business
Table 9. Vertex Genetic Disorders Drug Product and Services
Table 10. Vertex Genetic Disorders Drug Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Takeda Basic Information, Manufacturing Base and Competitors
Table 12. Takeda Major Business
Table 13. Takeda Genetic Disorders Drug Product and Services
Table 14. Takeda Genetic Disorders Drug Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Amgen Basic Information, Manufacturing Base and Competitors
Table 16. Amgen Major Business
Table 17. Amgen Genetic Disorders Drug Product and Services
Table 18. Amgen Genetic Disorders Drug Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. GW Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 20. GW Pharmaceuticals Major Business
Table 21. GW Pharmaceuticals Genetic Disorders Drug Product and Services
Table 22. GW Pharmaceuticals Genetic Disorders Drug Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Pfizer Basic Information, Manufacturing Base and Competitors
Table 24. Pfizer Major Business
Table 25. Pfizer Genetic Disorders Drug Product and Services
Table 26. Pfizer Genetic Disorders Drug Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. BioMarin Basic Information, Manufacturing Base and Competitors
Table 28. BioMarin Major Business
Table 29. BioMarin Genetic Disorders Drug Product and Services
Table 30. BioMarin Genetic Disorders Drug Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Sarepta Basic Information, Manufacturing Base and Competitors
Table 32. Sarepta Major Business
Table 33. Sarepta Genetic Disorders Drug Product and Services
Table 34. Sarepta Genetic Disorders Drug Sales (K Doses), Price (USD/Dose), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Global Genetic Disorders Drug Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Doses)
Table 36. Global Genetic Disorders Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 37. Market Position of Manufacturers in Genetic Disorders Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 38. Global Genetic Disorders Drug Production Capacity by Company, (K Doses): 2020 VS 2021
Table 39. Head Office and Genetic Disorders Drug Production Site of Key Manufacturer
Table 40. Genetic Disorders Drug New Entrant and Capacity Expansion Plans
Table 41. Genetic Disorders Drug Mergers & Acquisitions in the Past Five Years
Table 42. Global Genetic Disorders Drug Sales by Region (2017-2022) & (K Doses)
Table 43. Global Genetic Disorders Drug Sales by Region (2023-2028) & (K Doses)
Table 44. Global Genetic Disorders Drug Revenue by Region (2017-2022) & (USD Million)
Table 45. Global Genetic Disorders Drug Revenue by Region (2023-2028) & (USD Million)
Table 46. Global Genetic Disorders Drug Sales by Type (2017-2022) & (K Doses)
Table 47. Global Genetic Disorders Drug Sales by Type (2023-2028) & (K Doses)
Table 48. Global Genetic Disorders Drug Revenue by Type (2017-2022) & (USD Million)
Table 49. Global Genetic Disorders Drug Revenue by Type (2023-2028) & (USD Million)
Table 50. Global Genetic Disorders Drug Price by Type (2017-2022) & (USD/Dose)
Table 51. Global Genetic Disorders Drug Price by Type (2023-2028) & (USD/Dose)
Table 52. Global Genetic Disorders Drug Sales by Application (2017-2022) & (K Doses)
Table 53. Global Genetic Disorders Drug Sales by Application (2023-2028) & (K Doses)
Table 54. Global Genetic Disorders Drug Revenue by Application (2017-2022) & (USD Million)
Table 55. Global Genetic Disorders Drug Revenue by Application (2023-2028) & (USD Million)
Table 56. Global Genetic Disorders Drug Price by Application (2017-2022) & (USD/Dose)
Table 57. Global Genetic Disorders Drug Price by Application (2023-2028) & (USD/Dose)
Table 58. North America Genetic Disorders Drug Sales by Country (2017-2022) & (K Doses)
Table 59. North America Genetic Disorders Drug Sales by Country (2023-2028) & (K Doses)
Table 60. North America Genetic Disorders Drug Revenue by Country (2017-2022) & (USD Million)
Table 61. North America Genetic Disorders Drug Revenue by Country (2023-2028) & (USD Million)
Table 62. North America Genetic Disorders Drug Sales by Type (2017-2022) & (K Doses)
Table 63. North America Genetic Disorders Drug Sales by Type (2023-2028) & (K Doses)
Table 64. North America Genetic Disorders Drug Sales by Application (2017-2022) & (K Doses)
Table 65. North America Genetic Disorders Drug Sales by Application (2023-2028) & (K Doses)
Table 66. Europe Genetic Disorders Drug Sales by Country (2017-2022) & (K Doses)
Table 67. Europe Genetic Disorders Drug Sales by Country (2023-2028) & (K Doses)
Table 68. Europe Genetic Disorders Drug Revenue by Country (2017-2022) & (USD Million)
Table 69. Europe Genetic Disorders Drug Revenue by Country (2023-2028) & (USD Million)
Table 70. Europe Genetic Disorders Drug Sales by Type (2017-2022) & (K Doses)
Table 71. Europe Genetic Disorders Drug Sales by Type (2023-2028) & (K Doses)
Table 72. Europe Genetic Disorders Drug Sales by Application (2017-2022) & (K Doses)
Table 73. Europe Genetic Disorders Drug Sales by Application (2023-2028) & (K Doses)
Table 74. Asia-Pacific Genetic Disorders Drug Sales by Region (2017-2022) & (K Doses)
Table 75. Asia-Pacific Genetic Disorders Drug Sales by Region (2023-2028) & (K Doses)
Table 76. Asia-Pacific Genetic Disorders Drug Revenue by Region (2017-2022) & (USD Million)
Table 77. Asia-Pacific Genetic Disorders Drug Revenue by Region (2023-2028) & (USD Million)
Table 78. Asia-Pacific Genetic Disorders Drug Sales by Type (2017-2022) & (K Doses)
Table 79. Asia-Pacific Genetic Disorders Drug Sales by Type (2023-2028) & (K Doses)
Table 80. Asia-Pacific Genetic Disorders Drug Sales by Application (2017-2022) & (K Doses)
Table 81. Asia-Pacific Genetic Disorders Drug Sales by Application (2023-2028) & (K Doses)
Table 82. South America Genetic Disorders Drug Sales by Country (2017-2022) & (K Doses)
Table 83. South America Genetic Disorders Drug Sales by Country (2023-2028) & (K Doses)
Table 84. South America Genetic Disorders Drug Revenue by Country (2017-2022) & (USD Million)
Table 85. South America Genetic Disorders Drug Revenue by Country (2023-2028) & (USD Million)
Table 86. South America Genetic Disorders Drug Sales by Type (2017-2022) & (K Doses)
Table 87. South America Genetic Disorders Drug Sales by Type (2023-2028) & (K Doses)
Table 88. South America Genetic Disorders Drug Sales by Application (2017-2022) & (K Doses)
Table 89. South America Genetic Disorders Drug Sales by Application (2023-2028) & (K Doses)
Table 90. Middle East & Africa Genetic Disorders Drug Sales by Region (2017-2022) & (K Doses)
Table 91. Middle East & Africa Genetic Disorders Drug Sales by Region (2023-2028) & (K Doses)
Table 92. Middle East & Africa Genetic Disorders Drug Revenue by Region (2017-2022) & (USD Million)
Table 93. Middle East & Africa Genetic Disorders Drug Revenue by Region (2023-2028) & (USD Million)
Table 94. Middle East & Africa Genetic Disorders Drug Sales by Type (2017-2022) & (K Doses)
Table 95. Middle East & Africa Genetic Disorders Drug Sales by Type (2023-2028) & (K Doses)
Table 96. Middle East & Africa Genetic Disorders Drug Sales by Application (2017-2022) & (K Doses)
Table 97. Middle East & Africa Genetic Disorders Drug Sales by Application (2023-2028) & (K Doses)
Table 98. Genetic Disorders Drug Raw Material
Table 99. Key Manufacturers of Genetic Disorders Drug Raw Materials
Table 100. Direct Channel Pros & Cons
Table 101. Indirect Channel Pros & Cons
Table 102. Genetic Disorders Drug Typical Distributors
Table 103. Genetic Disorders Drug Typical Customers
List of Figures
Figure 1. Genetic Disorders Drug Picture
Figure 2. Global Genetic Disorders Drug Revenue Market Share by Type in 2021
Figure 3. Cystic Fibrosis (CF)
Figure 4. Duchenne Muscular Dystrophy (DMD)
Figure 5. Lysosomal Storage Disease (LSD)
Figure 6. Paroxysmal Nocturnal Hemoglobinuria (PNH)
Figure 7. Global Genetic Disorders Drug Revenue Market Share by Application in 2021
Figure 8. Clinic
Figure 9. Hospital
Figure 10. Global Genetic Disorders Drug Revenue, (USD Million) & (K Doses): 2017 & 2021 & 2028
Figure 11. Global Genetic Disorders Drug Revenue and Forecast (2017-2028) & (USD Million)
Figure 12. Global Genetic Disorders Drug Sales (2017-2028) & (K Doses)
Figure 13. Global Genetic Disorders Drug Price (2017-2028) & (USD/Dose)
Figure 14. Global Genetic Disorders Drug Production Capacity (2017-2028) & (K Doses)
Figure 15. Global Genetic Disorders Drug Production Capacity by Geographic Region: 2022 VS 2028
Figure 16. Genetic Disorders Drug Market Drivers
Figure 17. Genetic Disorders Drug Market Restraints
Figure 18. Genetic Disorders Drug Market Trends
Figure 19. Global Genetic Disorders Drug Sales Market Share by Manufacturer in 2021
Figure 20. Global Genetic Disorders Drug Revenue Market Share by Manufacturer in 2021
Figure 21. Genetic Disorders Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 22. Top 3 Genetic Disorders Drug Manufacturer (Revenue) Market Share in 2021
Figure 23. Top 6 Genetic Disorders Drug Manufacturer (Revenue) Market Share in 2021
Figure 24. Global Genetic Disorders Drug Sales Market Share by Region (2017-2028)
Figure 25. Global Genetic Disorders Drug Revenue Market Share by Region (2017-2028)
Figure 26. North America Genetic Disorders Drug Revenue (2017-2028) & (USD Million)
Figure 27. Europe Genetic Disorders Drug Revenue (2017-2028) & (USD Million)
Figure 28. Asia-Pacific Genetic Disorders Drug Revenue (2017-2028) & (USD Million)
Figure 29. South America Genetic Disorders Drug Revenue (2017-2028) & (USD Million)
Figure 30. Middle East & Africa Genetic Disorders Drug Revenue (2017-2028) & (USD Million)
Figure 31. Global Genetic Disorders Drug Sales Market Share by Type (2017-2028)
Figure 32. Global Genetic Disorders Drug Revenue Market Share by Type (2017-2028)
Figure 33. Global Genetic Disorders Drug Price by Type (2017-2028) & (USD/Dose)
Figure 34. Global Genetic Disorders Drug Sales Market Share by Application (2017-2028)
Figure 35. Global Genetic Disorders Drug Revenue Market Share by Application (2017-2028)
Figure 36. Global Genetic Disorders Drug Price by Application (2017-2028) & (USD/Dose)
Figure 37. North America Genetic Disorders Drug Sales Market Share by Type (2017-2028)
Figure 38. North America Genetic Disorders Drug Sales Market Share by Application (2017-2028)
Figure 39. North America Genetic Disorders Drug Sales Market Share by Country (2017-2028)
Figure 40. North America Genetic Disorders Drug Revenue Market Share by Country (2017-2028)
Figure 41. United States Genetic Disorders Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Canada Genetic Disorders Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Mexico Genetic Disorders Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Europe Genetic Disorders Drug Sales Market Share by Type (2017-2028)
Figure 45. Europe Genetic Disorders Drug Sales Market Share by Application (2017-2028)
Figure 46. Europe Genetic Disorders Drug Sales Market Share by Country (2017-2028)
Figure 47. Europe Genetic Disorders Drug Revenue Market Share by Country (2017-2028)
Figure 48. Germany Genetic Disorders Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. France Genetic Disorders Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. United Kingdom Genetic Disorders Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Russia Genetic Disorders Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Italy Genetic Disorders Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Asia-Pacific Genetic Disorders Drug Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Genetic Disorders Drug Sales Market Share by Application (2017-2028)
Figure 55. Asia-Pacific Genetic Disorders Drug Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific Genetic Disorders Drug Revenue Market Share by Region (2017-2028)
Figure 57. China Genetic Disorders Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Japan Genetic Disorders Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Korea Genetic Disorders Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. India Genetic Disorders Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Southeast Asia Genetic Disorders Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Australia Genetic Disorders Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. South America Genetic Disorders Drug Sales Market Share by Type (2017-2028)
Figure 64. South America Genetic Disorders Drug Sales Market Share by Application (2017-2028)
Figure 65. South America Genetic Disorders Drug Sales Market Share by Country (2017-2028)
Figure 66. South America Genetic Disorders Drug Revenue Market Share by Country (2017-2028)
Figure 67. Brazil Genetic Disorders Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Argentina Genetic Disorders Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Middle East & Africa Genetic Disorders Drug Sales Market Share by Type (2017-2028)
Figure 70. Middle East & Africa Genetic Disorders Drug Sales Market Share by Application (2017-2028)
Figure 71. Middle East & Africa Genetic Disorders Drug Sales Market Share by Region (2017-2028)
Figure 72. Middle East & Africa Genetic Disorders Drug Revenue Market Share by Region (2017-2028)
Figure 73. Turkey Genetic Disorders Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Egypt Genetic Disorders Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Saudi Arabia Genetic Disorders Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. South Africa Genetic Disorders Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Manufacturing Cost Structure Analysis of Genetic Disorders Drug in 2021
Figure 78. Manufacturing Process Analysis of Genetic Disorders Drug
Figure 79. Genetic Disorders Drug Industrial Chain
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 世界の遺伝性疾患薬市場2022年：嚢胞性線維症（CF）、デュシェンヌ型筋ジストロフィー（DMD）、リソソーム蓄積症（LSD）、発作性夜間ヘモグロビン尿症（PNH）(Global Genetic Disorders Drug Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • ペット用遺伝子検査キットのグローバル市場予測2023-2029
  • コルチコステロイド反応性疾患のグローバル市場2023年：注射、経口
  • 世界の不安障害・パニック障害治療薬市場2022年：抗うつ薬、抗不安薬
  • 世界の顎関節症（TMD）インプラント市場2022年：金属、シリコーン、その他
  • 世界の顎関節症（TMD）デバイス市場2022年：口腔副子、顎関節分析システム、インプラント、その他